PATENT COOPERATION TREATY



PCT

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY (Chapter II of the Patent Cooperation Treaty)

(PCT Article 36 and Rule 70)

l	m's or agent's file reference 417PCT711	FOR FURTHER A	CTION	See Form PCT/IPEA/416			
Internati	ional application No.	International filing da	te (day/month/year)	Priority date (day/month/year)			
PCT/JP2004/007692 03.06.20			4	06.06.2003			
	International Patent Classification (IPC) or national classification and IPC						
Applica	nt						
AST	ELLAS PHARMA	INC.					
1.	under Article 35 and transn	nitted to the applicant according t		International Preliminary Examining Authority			
2.	This REPORT consists of a	total of 7	sheets, including	ng this cover sheet.			
3.	This report is also accompa	nied by ANNEXES, comprising:					
	a. (sent to the app	licant and to the International Bu	reau) a total of	sheets, as follows:			
				amended and are the basis for this report and/or			
	sheets cor Instruction		by this Authority (see Ru	ule 70.16 and Section 607 of the Administrative			
				nsiders contain an amendment that goes beyond			
	Box.	sure in the international applicat	ion as filed, as indicated	in item 4 of Box No. I and the Supplemental			
	b. (sent to the Inte	ernational Bureau only) a total of	(indicate type and number	er of electronic carrier(s))			
	1 disk , containing a sequence listing and/or tables related thereto, in computer readable form only, as indicated in the Supplemental Box Relating to Sequence Listing (see						
		e Administrative Instructions).		culcular Box Relating to Sequence Disting (see			
4.	-	tions relating to the following iter	ns:				
	Box No. I B	asis of the report					
	Box No. II P	riority					
		on-establishment of opinion with	regard to novelty, inventive step and industrial applicability				
	Box No. IV L	ack of unity of invention					
	Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement						
	Box No. VI Certain documents cited						
	Box No. VII Certain defects in the international application						
l	Box No. VIII Certain observations on the international application						
Date of submission of the demand Date of completion of this report							
				•			
Name and mailing address of the IPEA/JP			Authorized officer				
	-						
l	1 37						

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No.

PCT/JP2004/007692

Box	No. I		Basis of the report				
1.	With	n regard cated un	to the language, this report is based on the international der this item.	al application in the language in which	it was filed, unless otherwise		
		This report is based on translations from the original language into the following language which is the language of a translation furnished for the purposes of:					
			international search (Rule 12.3 and 23.1(b))				
			publication of the international application (Rule 12.4)				
		L_J i	international preliminary examination (Rule 55.2 and/o	r 55.3)			
2.	rece	n regard iving Oj report):	gard to the elements of the international application, this report is based on (replacement sheets which have been furnished to the g Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to ort):				
	\boxtimes	the int	ernational application as originally filed/furnished				
		the de	scription:				
		pages			as originally filed/furnished		
		pages'		received by this Authority on			
		pages'	•	received by this Authority on			
	П	the cla	aims:				
		nos.			as originally filed/furnished		
		nos.*			any statement) under Article 19		
		nos.*		received by this Authority on			
		nos.*		received by this Authority on	***************************************		
	Ш	the dra	awings:				
		sheets			as originally filed/furnished		
		sheets	*	received by this Authority on			
		sheets	*	received by this Authority on			
	\boxtimes	a sequ	ence listing and/or any related table(s) - see Suppleme	ntal Box Relating to Sequence Listing.			
3.		The ar	mendments have resulted in the cancellation of:				
			the description, pages				
			the claims, nos.				
			the drawings, sheets/figs				
			the sequence listing (specify):				
			any table(s) related to sequence listing (specify):				
4.		This r	report has been established as if (some of) the amenda	nents annexed to this report and listed	below had not been made, since		
			the description, pages	•	, ,,,		
		$\overline{}$					
*	If ite	т 4 арр	olies, some or all of those sheets may be marked "super	rseded."			

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No.
PCT/JP2004/007692

Вох	No. I	V Lack of unity of invention	
1.		In response to the invitation to restrict or pay additional fees the applicant has:	
		restricted the claims.	
		paid additional fees.	
		paid additional fees under protest.	
		neither restricted the claims nor paid additional fees.	
2.		This Authority found that the requirement of unity of invention is not complied with and chose, according to Rule 68.1, not to invite the applicant to restrict or pay additional fees.	
3.	This	Authority considers that the requirement of unity of invention in accordance with Rules 13.1, 13.2 and 13.3 is:	
		complied with.	
	\bowtie	not complied with for the following reasons:	
		The group of inventions that is set forth in	
		claims 1 to 6 (invention group A) includes inventions	
		that are related to the angiopoietin-related growth	
		factor. Meanwhile, the invention that is set forth in	
		claim 7 (invention B) is related to non-human knockout	
		animals in which the gene that codes the angiopoietin-	
		related growth factor has been deleted, and the	
		invention that is set forth in claim 8 (invention C)	
		is related to non-human transgenic mice that are	
		capable of expressing the angiopoietin-related growth	
		factor.	
		Invention Group A and Invention B	
		It is apparent that there is no technical	
		relationship involving one or more of the same or	
		corresponding special technical features among	
		invention group A and invention B.	
		[Refer to the Supplemental Box]	
4.	Con	sequently, this report has been established in respect of the following parts of the international application:	
		all parts.	
	\boxtimes	the parts relating to claims Nos. 1-6	

International application No.
PCT/JP2004/007692

Вох		Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; attations and explanations supporting such statement		
1.	Statement			
	Novelty (N)	Claims	1-6	YES
		Claims		NO
	Inventive step (IS)	Claims	5, 6	YES
		Claims	1-4	NO
	Industrial applicability (IA)	Claims	1-6	YES
		Claims		NO

2. Citations and explanations (Rule 70.7)

Document 1: JP 2000-300263 A (Helix Research Institute), 31 October 2000, entire text (Family: none)

Document 2: WO 99/15653 A1 (GENENTECH, INC.), 01 April 1999, entire text & EP 10155585 A2 & JP 2001-517437 A

Claims 1 to 4

The inventions set forth in claims 1 to 4 do not involve an inventive step in the light of the inventions that are disclosed in documents 1 and 2 cited in the international search report.

Documents 1 and 2 can be considered to disclose the gene that codes the angiopoietin-related growth factor in humans along with the base sequence thereof. In addition, it was common technical knowledge prior to the priority date of the present application that in cases when a given gene is well known, it is possible to acquire the promoter of said gene by means of genetic engineering techniques.

Therefore, it would have been easy for a person skilled in the art to conceive of attempting to acquire the promoter of the gene that codes the human angiopoietin-related growth factor by means of a genetic

International application No.
PCT/JP2004/007692

Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

engineering technique which employs probes and/or primers that have been created based on the base sequences that are disclosed in documents 1 and 2. At that time, a person skilled in the art could have searched upstream from the gene that codes the human angiopoietin-related growth factor in order to acquire DNA fragments that exhibit a high promoter activity, as appropriate.

In addition, a person skilled in the art could produce a recombinant vector comprising a promoter that has been obtained in this manner, and could produce a transformant comprising said recombinant vector, as appropriate.

Furthermore, there cannot be considered to be any especially significant effects that result from employing the configurations of the inventions that are set forth in claims 1 to 4 of the present application.

Claims 5 and 6

The inventions set forth in claims 5 and 6 are not disclosed in any of the documents that are cited in the international search report, and would not have been obvious to a person skilled in the art.

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No.

PCT/JP2004/007692

International application No.

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

PCT/JP2004/007692

Supplemental Box

In case the space in any of the preceding boxes is not sufficient. Continuation of:

Box IV

Invention Group A and Invention C

It is apparent that there is no technical relationship involving one or more of the same or corresponding special technical features among invention group A and invention C.

Invention B and Invention C

Invention B and invention C share the common feature of being inventions which are related to the "angiopoietin-related growth factor that is set forth in the present application." However, the angiopoietin-related growth factor that is set forth in the present application was well known prior to the priority date of the present application (if necessary, refer to the documents JP 2000-300263 A, WO 99/15653 A1 and the like); therefore, there cannot be considered to be a technical relationship involving one or more of the same or corresponding special technical features among invention B and invention C.

As a result, the inventions that are set forth in claims 1 to 8 do not conform to the requirement of unity of invention.

However, the inventions that are set forth in claims 1 to 6 can be considered to conform to the requirement of unity of invention.